(Press-News.org) *Note: this is a joint press release from the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) and The Lancet Infectious Diseases. Please credit both the congress and the journal in your stories*
Since September, 2022, bivalent mRNA vaccines – which contain elements from both the original wild type COVID strain and an updated component from the omicron strain – have replaced older style monovalent boosters in the USA, Israel, and other countries. These vaccines were designed to help improve vaccine-induced immunity against the omicron variant and subsequent subvariants.
A new study published in The Lancet Infectious Diseases and presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2023, Copenhagen 15-18 April) is one of first the assess the effectiveness of this new type of COVID-19 vaccine in vulnerable people aged 65 years and over. The study assessed the Pfizer bivalent vaccine, since Pfizer is the main supplier of COVID vaccines to Israel. The study shows that, compared to people in this age group eligible to receive this bivalent booster yet who did not, those receiving it had a 72% lower risk of COVID-19 related hospitalisation and a 68% lower risk of COVID-19 related death.
“Bivalent mRNA booster vaccination in adults aged 65 years or older is an effective and essential tool to reduce their risk of hospitalisation and death due to COVID-19. Vaccination remains the primary tool for avoiding severe COVID-19,” explains study co-author Dr Ronen Arbel, Community Medical Services Division, Clalit Health Services, Tel Aviv, and the Maximizing Health outcomes Research Lab, Sapir College, Sderot, Israel. “Our findings highlight the importance of new types of vaccines containing different variants of SARS-CoV-2, which are likely to induce broader immune responses and provide enhanced protection against severe outcomes.”
To date, randomised controlled trials evaluating the clinical efficacy of a bivalent mRNA booster vaccine are unavailable. The bivalent mRNA booster vaccines are currently prioritised in Israel for people at high risk of severe COVID-19, primarily those aged 65 years or older. This made it possible for the authors to do a retrospective cohort study to evaluate the effectiveness of a bivalent mRNA vaccine booster dose to prevent hospitalisations and deaths due to COVID-19.
Between Sept 27, 2022, and Jan 25, 2023, 569 519 eligible participants were identified. Of those, 134 215 (24%) participants received a bivalent mRNA booster vaccination during the study period. Hospitalisation due to COVID-19 occurred in 32 participants who received a bivalent mRNA booster vaccination and 541 who did not receive a bivalent booster vaccination (with analysis showing this to mean a 72% reduction in the risk of hospitalisation for those receiving the bivalent booster). The adjusted risk for Covid-19 hospitalisations in the bivalent mRNA booster recipients was 0.035% versus 0.124% in the non-recipients. Therefore the absolute risk reduction for hospitalisations due to COVID-19 was 0·089%, and accordingly, one hospitalisation due to COVID-19 was avoided for every 1118 people vaccinated.
The adjusted risk for Covid-19 death was 0.013% in the bivalent mRNA booster recipients versus 0.040% in the non-recipients, meaning a 68% relative risk reduction death for the bivalent vaccine recipients. The absolute risk reduction of death was 0·027%, and accordingly, one death due to COVID-19 was avoided for every 3722 people vaccinated.
The authors note some limitations of their study, including the low numbers of hospitalisations and deaths, and that use of only the Pfizer bivalent vaccine means that generalisation of the results to other bivalent vaccines should be done with caution. Also, the study was not a direct comparison between bivalent and monovalent vaccines, since both were not administered at the same time in Israel during the study period. They also note adverse events are outside the scope of the study, but note that “preliminary short-term safety results published by the CDC have shown a comprehensive safety profile for the bivalent booster and reassured that adverse events reported after a bivalent booster dose are consistent with those reported after monovalent doses”.
The authors conclude: “Our results suggest that the bivalent mRNA vaccine booster dose is associated with a reduced risk of severe COVID-19 outcomes in adults aged 65 years
or older. Our findings highlight the importance of bivalent booster vaccination in populations at high risk of severe COVID-19 and the necessity to increase efforts to encourage eligible people to be vaccinated.”
Dr Ronen Arbel, Community Medical Services Division, Clalit Health Services, Tel Aviv, Israel. T) +972-524-777-847 E) ronen.arbel@gmail.com
Alternative contact Tony Kirby in the ECCMID Media Centre. T) +44 7834 385827 E) tony@tonykirby.com
The Lancet Infectious Diseases: Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study
To be presented at a special Lancet journals COVID-19 session in Hall I of the European Congress on Clinical Microbiology & Infectious Diseases (ECCMID 2023) in Copenhagen on Monday April 17 at 16.15-18.15 Copenhagen time (CEST).
END
One of first studies to assess new bivalent Covid-19 booster vaccine shows it is highly effective in reducing deaths and hospitalizations
2023-04-14
ELSE PRESS RELEASES FROM THIS DATE:
A $1 million boost to UT’s venture culture
2023-04-14
Adding fuel to The University of Texas at Austin’s startup engine, alumnus William “Billy” Freed, BBA ’81, and his family have given $1 million to the Herb Kelleher Entrepreneurship Center in the McCombs School of Business.
The gift establishes the Freed Family Entrepreneurship Excellence Fund and endows the Freed Family Pitch Competition, previously called DisrupTexas. Freed’s wife Cheryl, BA ’82, JD ’84; sons Tyler, BS ’17, and Russell, BBA ’21; and daughter-in-law Leslie Lugrin Freed, BS ’17, ...
Data can now be processed at the speed of light!
2023-04-14
How can Marvel movie character Ant-Man produce such strong energy out of his small body? The secret lies in the “transistors” on his suit that amplify weak signals for processing. Transistors that amplify electrical signals in the conventional way lose heat energy and limit the speed of signal transfer, which degrades performance. What if it were possible to overcome such limitation and make a high-performance suit that is light and small but without loss of heat energy?
A POSTECH team of Professor Kyoung-Duck Park and Yeonjeong Koo from the Department of Physics and a team from ...
Disrupted rhythms of rest and wakefulness contribute to worse symptoms in schizophrenia patients
2023-04-14
PITTSBURGH, April 13, 2023 – In a paper published today in Molecular Psychiatry, a team of scientists from the University of Pittsburgh in collaboration with researchers in Italy described shared patterns of sleep disturbances and irregularities in daily rhythms of rest and activity across patients with schizophrenia spectrum disorder, or SSD.
By using wrist monitors that measured activity and rest as proxies of wakefulness and sleep, researchers found that individuals with SSD who resided in psychiatric hospitals and those who manage their condition in outpatient settings had erratic sleep patterns, dysregulated transitions between sleep ...
How AI and a mobile phone app could help you quit smoking
2023-04-14
A stop smoking mobile app that senses where and when you might be triggered to light up could help people quit – according to University of East Anglia research.
Quit Sense is the world’s first Artificial Intelligence (AI) stop smoking app which detects when people are entering a location they used to smoke in. It then provides support to help manage people’s specific smoking triggers in that location.
Funding for the Quit Sense app has come from the National Institute for Health and Care Research (NIHR) and the Medical Research Council.
A study published today shows how the new ...
Nurse sounds a warning on hearing loss for COVID-19 patients
2023-04-14
A University of South Australia nursing lecturer has used her own COVID-19 experience to inform research into a little-known side effect of the virus – sudden deafness.
Kim Gibson, a registered nurse with a clinical background in neonatal intensive care, has documented her experience with sudden sensorineural hearing loss (SSNHL) five weeks after testing positive to COVID-19. She was fully vaccinated.
Her findings and recommendations are published in the latest edition of the British Medical Journal Case Reports.
Gibson developed acute hearing loss in one ear, along with ...
Scientists from Singapore and Sweden achieve promising results towards restoring vision in blindness caused by cellular degeneration in the eye
2023-04-14
SINGAPORE, 14 April 2023 – A preclinical study using stem cells to produce progenitor photoreceptor cells—light-detecting cells found in the eye—and then transplanting these into experimental models of damaged retinas has resulted in significant vision recovery. This finding, by scientists at Duke-NUS Medical School, the Singapore Eye Research Institute and the Karolinska Institute in Sweden, marks a first step towards potentially restoring vision in eye diseases characterised by photoreceptor loss.
“Our laboratory has developed a novel method that enables the production of photoreceptor ...
IOP Publishing celebrates World Quantum Day with the announcement of a special quantum collection and the winners of two prestigious quantum awards
2023-04-14
In celebration of World Quantum Day (14th April), IOP Publishing (IOPP) is launching a special collection of its most popular, cutting-edge quantum research published in the last two years.
The IOPP quantum collection is openly available for anyone to read and showcases world-class quantum research published in the academic journals Materials for Quantum Technology, Quantum Science and Technology, New Journal of Physics and Reports on Progress in Physics. The special collection will also include unique perspectives from women in quantum and their contributions to this popular field.
Quantum research and technology is evolving ...
Toppan and Hokkaido University launch Comprehensive Dementia Research Unit
2023-04-14
Tokyo – April 13, 2023 – Toppan (TYO: 7911), a global leader in communication, security, packaging, décor materials, and electronics solutions, and Hokkaido University have launched the “Comprehensive Dementia Research Unit,” an industry creation section that will collaborate with the Hokkaido University Collaborative Project Center’s Cognitive Science Research Center, which conducts comprehensive research on diagnosis technologies for dementia.
Fusing Toppan’s Digital ICA™1 technology for high-sensitivity ...
Safe bioink for artificial organ printing
2023-04-14
The development of biomaterials for artificial organs and tissues is active due to an increase in accidental injuries and chronic diseases, along with the entry into a super-aged society. 3D bioprinting technology, which uses cells and biomaterials to create three-dimensional artificial tissue structures, has recently gained popularity. However, commonly used hydrogel-based bioinks can cause cytotoxicity due to the chemical crosslinking agent and ultraviolet light that connect the molecular structure of photocuring 3D-printed bioink.
Dr. Song Soo-chang's research team at ...
Researchers turn to the power of native aquatic plants to clean coastal waters
2023-04-14
To find a fast, efficient way to clear harmful chemicals along the Gulf of Mexico coastline, researchers are turning to something already familiar with the task – several species of the aquatic grasses and rice that feel very much at home in murky coastal waters.
The research team led by University of Houston’s Venkatesh Balan, associate professor of biotechnology in the Cullen College of Engineering’s Division of Technology, studies the abilities of these water-loving flora to uptake concentrations ...